Premium
The immunogenicity of Haemophilus influenzae: Meningococcal protein conjugate vaccine in Polynesian and non‐Polynesian New Zealand infants
Author(s) -
AMERATUNGA SN,
LEN DR,
ENTWISTLE B,
ROBINSON E,
AMERATUNGA RV
Publication year - 1997
Publication title -
journal of paediatrics and child health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.631
H-Index - 76
eISSN - 1440-1754
pISSN - 1034-4810
DOI - 10.1111/j.1440-1754.1997.tb01016.x
Subject(s) - immunogenicity , medicine , vaccination , booster dose , antibody , haemophilus influenzae , conjugate vaccine , booster (rocketry) , meningococcal disease , meningococcal vaccine , epidemiology , neisseria meningitidis , pediatrics , virology , immunology , immunization , microbiology and biotechnology , bacteria , physics , genetics , astronomy , biology , antibiotics
Objective: To examine the comparative immunogenicity of the Haemophilus influenzae type b‐meningococcal protein (PRP‐OMP) conjugate vaccine in Polynesian and non‐Polynesian New Zealand infants. Methodology: Fifty‐six Polynesian and 53 non‐Polynesian infants aged 2–7 months recruited from primary health care settings in Auckland received a two‐dose primary series of PRP‐OMP. A sub‐sample of 83 participants received a booster dose of PRP‐OMP at 12–16 months of age. Anti‐PRP antibody concentrations were measured in pre‐ and post‐vaccination blood samples. Results: Antibody responses consistent with long‐term protection (≥1.00 μg/mL) were observed in 72, 85 and 95% of children following the first, second and booster doses. Conclusions: Despite differences in disease epidemiology, PRP‐OMP was highly immunogenic in Polynesian and non‐Polynesian infants.